Physiomics are delighted to attend the 37th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”), being held on 8-12 November 2022 in Boston, USA.
We will be exhibiting at the event (booth #236) and presenting an original poster on the preclinical PK/PD relationship for NM32-2668 (“NM32”), a ROR1 targeting T cell engager, co-authored with one of our clients.
We look forward to meeting new and existing clients alike, who are committed to developing novel immunotherapies for the treatment of cancer and discussing how we can help in this endeavour.
Schedule a meeting or pop by our booth to say “Hello”.
We’re agile, flexible, responsive and collaborative. We work with you to solve real development challenges.
Your PK/PD data is analysed and interpreted by people who understand oncology.
We offer bespoke modelling solutions and our Virtual Tumour™ platform to answer your development questions.